文献速递淋巴瘤

PI3Kδ抑制调节慢性淋巴细胞白血病中调节性T细胞与效应T细胞的分化及功能

PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2018-12-20

该研究利用Eµ-TCL1过继转移慢性淋巴细胞白血病(CLL)小鼠模型,发现疾病发展诱导活化且高免疫抑制性的调节性T细胞(Treg)积聚;抗CD25抗体清除CD25+ Treg可增强CD8+ T细胞活化、效应分化与功能;PI3Kδ抑制剂有效控制疾病并减少CD25+与CD25- Treg数量、增殖和活化,但未改善CD8+ T细胞功能,因同时削弱CD8+ T细胞受体信号。

要点

  • CLL疾病发展诱导活化且高免疫抑制性Treg积聚。
  • 抗CD25抗体清除CD25+ Treg增强CD8+ T细胞活化、效应分化与功能。
  • PI3Kδ抑制减少Treg但未改善CD8+ T细胞功能,因削弱其TCR信号。

核心结论

  • PI3Kδ抑制剂在CLL中具有强免疫调节效应,对合理设计基于idelalisib的联合治疗具有相关性。

研究设计与样本

  • 使用Eµ-TCL1过继转移CLL小鼠模型开展研究。

主要发现

  • CLL疾病发展诱导活化且高免疫抑制性Treg积聚。
  • 抗CD25抗体清除CD25+ Treg导致CD8+ T细胞活化、效应分化及功能增强。
  • PI3Kδ药理抑制有效控制疾病并显著降低CLL荷瘤小鼠CD25+与CD25- Treg数量、增殖及活化状态。
  • PI3Kδ抑制介导的Treg减少未转化为更好的CD8+ T细胞功能,因同时削弱CD8+ T细胞TCR信号,导致活化、效应细胞分化与增殖降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeting B-cell receptor signaling using the PI3Kδ inhibitor idelalisib is a highly effective treatment option for relapsed/refractory chronic lymphocytic leukemia (CLL) patients. In addition to its direct impact on tumor cells, PI3Kδ inhibition can modulate the activity of regulatory T-cells (Tregs) resulting in enhanced anti-tumoral immune functions which may contribute to the success of PI3Kδ inhibitors in cancer therapy. The role of Tregs in CLL and their modulation by PI3Kδ inhibitors was so far poorly understood. Using the Eµ-TCL1 adoptive transfer model of CLL, we show that disease development induces the accumulation of activated and highly immunosuppressive Tregs. Depletion of CD25+ Tregs using anti-CD25 antibodies resulted in enhanced CD8+ T-cell activation, effector differentiation, and functional capacity. We further show that pharmacological inhibition of PI3Kδ effectively controlled disease and significantly decreased both CD25+ and CD25- Treg numbers, proliferation and activation status in CLL-bearing mice. Nonetheless, this PI3Kδ-mediated decrease in Tregs did not translate into better CD8+ T-cell function, as PI3Kδ inhibition concomitantly abrogated T-cell receptor signaling in CD8+ T-cells leading to decreased activation, effector cell differentiation and proliferation. Collectively, these data highlight the strong immunomodulatory effects of PI3Kδ inhibitors in CLL and are of relevance for a rational design of idelalisib-based combination therapies in CLL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hanna BS, Roessner PM, Scheffold A, et al. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Leukemia. 2018. PMID: 30573773. doi:10.1038/s41375-018-0318-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。